CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Epstein-Barr Virus Specific Immunotherapybiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00834093
NCT00834093Phase 2Completed
CompareCT.gov

A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma

Dana-Farber Cancer Institute·interventional·Posted Feb 3, 2009·Updated Jun 28, 2023

In Brief

A Phase 2 clinical trial evaluating Epstein-Barr Virus Specific Immunotherapy for Nasopharyngeal Carcinoma. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

The purpose of this research study is to determine how effective and how safe it is to give an Epstein-Barr Virus (EBV) immunotherapy product to participants with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the participant's body. This is phase II study with the aim of establishing a baseline of efficacy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNasopharyngeal Carcinoma
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Massachusetts General Hospital, National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedFeb 3, 2009
Enrollment StartApr 1, 2009
Primary CompletionMar 1, 2012
Study CompletionFeb 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 17.4 years ago

Interventions

Epstein-Barr Virus Specific Immunotherapybiological